

A Present Update of Camostate and the Role in SARS-CoV-2 Infection

Stefan Bittmann*

Keywords: SARS-CoV2; S-protein; Camostate; Protease.

SARS-CoV-2 has triggered a pandemic of "coronavirus disease-2019" (Covid-19). Viral cell entry of coronaviruses relies on the binding of viral spike protein (S protein) to cellular receptors and S type of protein processing by the host cell proteases. It is known that SARS-CoV-2 uses the human receptor ACE2 for cell entry and the serine protease TMPRSS2 for "priming" of the S protein. Camostate has antiviral properties against coronaviruses. The effects are due to inhibition of the endogenous protease TMPRSS2, which the SARS-CoV-2 virus requires for the host cell entry (as well as exit). Camostate is a serine protease inhibitor. Camostate, which is already in clinical use, reduces cell infection. So far, this has been shown exclusively in cell lines or cell cultures, which do not reflect the complexity of the three-dimensional alveolar lung cell association with type I, type II cells, endothelial cells and alveolar macrophages. It is well known, that Camostate blocks TMPRSS2 and related proteases [1-36]. For SARS-CoV-2 to enter lung cells, the virus must be activated by the cellular protease TMPRSS2. Camostate is used in Japan to treat inflammation of the pancreas, blocks the protease TMPRSS2 and thereby inhibit SARS-CoV-2[1-18,20-29,31-35]. However, it was unclear whether the camostate degradation product GBPA also inhibits the virus and whether the virus can use related proteases for infection in addition to TMPRSS2, which may not be inhibited by camostate [18,20,29]. These proteases are available to the virus for replication in the upper respiratory tract and are inhibited by camostate [1-36]. It is therefore not possible for SARS-CoV-2 to evade the antiviral effect of Camostate by switching to related proteases instead of TMPRSS2. In further studies, the researchers were able to show that in addition to Camostate, the primary Camostate metabolite GBPA also inhibits the protease TMPRSS2, thereby blocking SARS-

¹Ped Mind Institute, Department of Pediatrics, Hindenburgring 4, D-48599 Gronau, Germany.

*Corresponding Author: Stefan Bittmann, Ped Mind Institute, Department of Pediatrics, Hindenburgring 4, D-48599 Gronau, Germany.

Received Date: 05-14-2022

Accepted Date: 05-19-2022

Published Date: 06-15-2022

Copyright© 2022 by Bittmann S. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CoV-2 infection. Camostate is converted to GBPA in the body within a very short time. GBPA can exert an antiviral effect in patients. A higher dosage of Camostate to effectively treat COVID-19 than to treat pancreatic inflammation may be required [33,36]. Inhibition of SARS-CoV-2 by Camostate had initially been shown only in the lung cell line Calu-3 [6]. The involvement of researchers from Hannover, Germany, made it possible to analyze the antiviral effect of Camostate in real lung tissue as well [6]. Camostate and GBPA inhibit SARS-CoV-2 infection of lung tissue [15]. The camostate mesilate-containing drug Foipan® has been available on the Japanese market since 1986 [1-36]. It is used to treat chronic inflammation of the pancreas and postoperative reflux esophagitis [33,36]. According to the product information, the substance has an inhibitory effect on several enzymes and intervenes in various systems in the body. Among other things, an inhibitory effect on trypsin and normalization of amylase levels are mentioned [33,36]. However, the reason why this substance suddenly becomes interesting in the corona crisis is different [24,26,30].

Camostate is defined as 4-[[4-[(Aminoiminomethyl)amino]benzoyl]oxy]benzen-essigsäure 2-(Dimethylamino)-2-oxoethylester-methansulfonat; FOY 305; FOY-S 980; Foipan -mesylat) [1-36]. The empirical formula is $C_{20}H_{22}N_4O_5 \cdot CH_3S_3H$ [24,35]. The molecular weight is 494.52. The melting point is between 164-168 degrees. Camostate is stored in the refrigerator. The UN No. is 3077, the CAS No. is 59721-29-8. Camostate belongs to the protease inhibitor class of drugs, and its mechanism of action is antifibrinolysis [1-36]. Camostate is a synthetically produced active ingredient from the protease inhibitor group [1-36]. It is approved in Japan as Foipan (manufacturer: Ono Pharmaceutical) for the oral treatment of chronic pancreatitis and postoperative esophagitis caused by reflux of gastric acid [33,36]. Chemically, camostate is a derivative of p-aminobenzoic acid. The active ingredient is used medicinally as camostate mesilate, i.e., as the salt of methanesulfonic acid [1-36]. Camostate inhibits in vitro various pancreatic and plasmatic proteolytic enzymes such as trypsin, plasmin, pancreatic kallikrein, plasma kallikrein, and thrombin, as well as the hydrolytic activity of C_{1r} and C₁ esterase [33,36]. Camostate further inhibits the cellular protease TMPRSS₂ in vitro [1-18,20-29,31-32,34,35]. The efficacy of Camostate in different cell cultures has already been demonstrated [1-36]. Camostates inhibits TMPRSS₂, the enzyme is expressed on the human cell surface after autocatalytic activation, mainly in the small intestine and to a lesser extent in the liver, heart, prostate, thymus and lung [1-36]. As per the analysis, SARS-CoV-2, virus responsible for the COVID-19, requires TMPRSS₂ exists in human body to get inside the host cell, which may provide target for the treatment [1-18,20-29,31,32,34,35]. Therapeutic efficacy in COVID-19 patients remains to be tested in clinical trials [2-4,6,24,32]. Similarly, it is to be investigated whether active elements can be injected directly to the lungs. It is unclear whether camostate per se is sufficiently available in the lungs. According to scientific information of the German Federal Institute for Drugs and Medical Devices, the necessary doses, extrapolated from results obtained in cell cultures, would be so strong in patients of standard weight that serious side effects could occur. Camostate is among drugs for which the German Federal Ministry of Health started the central appropriation in April 2020 for the treatment of the

infection along with severely ill cases of COVID-19 patients in Germany. Since the COVID-19 therapy an individual therapeutic trial without any clinical evidence of virtue, its usage must be implemented on the patient-by-patient basis, primarily for severe forms of the disease.

References

1. Breining P, Frølund AL, Højen JF, Gunst JD, Staerke NB, Saedder E, et al. Camostate mesylate against SARS-CoV2 and COVID-19—Rationale, dosing and safety. *Basic Clin Pharmacol Toxicol*. 2021;128(2):204-12. [PubMed](#) | [CrossRef](#)
2. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181(2):271-80. [PubMed](#) | [CrossRef](#)
3. Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Arora P, Sørensen LK, et al. Camostate mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. *EBioMedicine*. 2021;65:103255. [PubMed](#) | [CrossRef](#)
4. Gunst JD, Staerke NB, Pahus MH, Kristensen LH, Bodilsen J, Lohse N, et al. Efficacy of the TMPRSS2 inhibitor camostate mesilate in patients hospitalized with Covid-19—a double-blind randomized controlled trial. *EClinicalMedicine*. 2021;35:100849. [PubMed](#) | [CrossRef](#)
5. Uno Y. Camostate mesilate therapy for COVID-19. *Intern Emerg Med*. 2020;15(8):1577-8. [PubMed](#) | [CrossRef](#)
6. Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Arora P, Sørensen LK, et al. Camostate mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. *EBioMedicine*. 2021;65:103255. [CrossRef](#)
7. Hofmann-Winkler H, Moerer O, Alt-Epping S, Bräuer A, Büttner B, Müller M, Fricke T, et al. Camostate Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation. *Crit Care Explor*. 2020;2(11):0284. [PubMed](#) | [CrossRef](#)
8. McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. *Pharmacol Res*. 2020;157:104859. [PubMed](#) | [CrossRef](#)
9. Sakr Y, Bensasi H, Taha A, Bauer M, Ismail K. Camostate mesylate therapy in critically ill patients with COVID-19 pneumonia. *Intensive Care Medicine*. 2021;47(6):707-9. [PubMed](#) | [CrossRef](#)
10. Sun G, Sui Y, Zhou Y, Ya J, Yuan C, Jiang L, et al. Structural basis of covalent inhibitory mechanism of TMPRSS2-related serine proteases by camostate. *J Virol*. 2021;95(19):00861-21. [PubMed](#) | [CrossRef](#)
11. Kumar BK, Sekhar KV, Kunjiappan S, Jamal J, Balaña-Fouce R, Tekwani BL, et al. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. *Bioorg Chem*. 2020;104:104269. [PubMed](#) | [CrossRef](#)
12. Sørensen LK, Hasselstrøm JB, Gunst JD, Søgaard OS, Kjolby M. Determination of camostate and its metabolites in human plasma - Preservation of samples and quantification by a validated UHPLC-MS/MS method. *Clin Biochem*. 2021;96:56-62. [PubMed](#) | [CrossRef](#)
13. Yuan L, Li M, Zhang Z, Li W, Jin W, Wang M. Camostate mesilate inhibits pro-inflammatory cytokine secretion and improves cell viability by regulating MFG8 and HMG1 in lipopolysaccharide-stimulated DF-1 chicken embryo fibroblasts. *Peer J*. 2021;9:12053. [PubMed](#) | [CrossRef](#)
14. Neary M, Box H, Sharp J, Tatham L, Curley P, Herriott J, et al. Evaluation of intranasal nafamostat or camostate for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters. *bioRxiv*. 2021;2021.07.08.451654. [PubMed](#) | [CrossRef](#)
15. Weiss J, Bajraktari-Sylejmani G, Haefeli WE. Low risk of the TMPRSS2 inhibitor camostate mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions. *Chem Biol Interact*. 2021;338:109428. [PubMed](#) | [CrossRef](#)

16. Kitagawa J, Arai H, Iida H, Mukai J, Furukawa K, Ohtsu S, Nakade S, et al. A phase I study of high dose camostate mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19. *Clin Transl Sci.* 2021;14(5):1967-76. [PubMed](#) | [CrossRef](#)
17. Mizumoto T, Kakizoe Y, Nakagawa T, Iwata Y, Miyasato Y, Uchimura K. A serine protease inhibitor camostate mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. *J Pharmacol Sci.* 2021;146(4):192-9. [PubMed](#) | [CrossRef](#)
18. Zhu H, Du W, Song M, Liu Q, Herrmann A, Huang Q. Spontaneous binding of potential COVID-19 drugs (Camostate and Nafamostat) to human serine protease TMPRSS2. *Comput Struct Biotechnol J.* 2020;19:467-476. [PubMed](#) | [CrossRef](#)
19. Yamawaki H, Futagami S, Kaneko K, Agawa S, Higuchi K, Murakami M, et al. Camostate mesilate, pancrelipase, and rabeprazole combination therapy improves epigastric pain in early chronic pancreatitis and functional dyspepsia with pancreatic enzyme abnormalities. *Digestion.* 2019;99(4):283-92. [CrossRef](#)
20. Liu T, Luo S, Libby P, Shi GP. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. *Pharmacol Ther.* 2020;213:107587. [PubMed](#) | [CrossRef](#)
21. Oroojalian F, Haghbin A, Baradaran B, Hemmat N, Shahbazi MA, Baghi HB, et al. Novel insights into the treatment of SARS-CoV-2 infection: an overview of current clinical trials. *Int J Biol Macromol.* 2020;165:18-43. [PubMed](#) | [CrossRef](#)
22. Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. *Emerg Microbes Infect.* 2022;11(1):277-83. [PubMed](#) | [CrossRef](#)
23. Ragia G, Manolopoulos VG. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. *Eur J Clin Pharmacol.* 2020;76(12):1623-30. [PubMed](#) | [CrossRef](#)
24. Halford S, Wan S, Dragoni I, Silvester J, Nazarov B, Anthony D, et al. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostate in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. *Trials.* 2021;22(1):550. [PubMed](#) | [CrossRef](#)
25. Escalante DE, Ferguson DM. Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostate bound to the trypsin-like protease TMPRSS2. *Med Chem Res.* 2021;30(2):399-409. [PubMed](#) | [CrossRef](#)
26. Ramakrishnan J, Kandasamy S, Iruthayaraj A, Magudeeswaran S, Chinnasamy K, Poomani K. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostate and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations. *Appl Biochem Biotechnol.* 2021;193(6):1909-23. [PubMed](#) | [CrossRef](#)
27. Bittmann S, Weissenstein A, Villalon G, Moschuring-Alieva E, Luchter E. Simultaneous treatment of COVID-19 with serine protease inhibitor camostate and/or cathepsin L inhibitor? *J Clin Med Res.* 2020;12(5):320. [PubMed](#) | [CrossRef](#)
28. Sonawane KD, Barale SS, Dhanavade MJ, Waghmare SR, Nadaf NH, Kamble SA, et al. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostate mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach. *Inform Med Unlocked.* 2021;24:100597. [PubMed](#) | [CrossRef](#)
29. Li K, Meyerholz DK, Bartlett JA, McCray Jr PB. The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19. *MBio.* 2021;12(4):00970-21. [PubMed](#) | [CrossRef](#)
30. Maekawa A, Kakizoe Y, Miyoshi T, Wakida N, Ko T, Shiraishi N, et al. Camostate mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. *J Hypertens.* 2009;27(1):181-9. [PubMed](#) | [CrossRef](#)
31. Hussman JP. Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. *Front Pharmacol.* 2020;11:1169. [PubMed](#) | [CrossRef](#)

32. Chupp G, Spichler-Moffarah A, Sogaard OS, Esserman D, Dziura J, Danzig L, et al. A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostate Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste. medRxiv. 2022.
33. Furukawa F, Nishikawa A, Imazawa T, Yoshimura H, Sato M, Aze Y, et al. Blocking effects of synthetic trypsin inhibitor (camostate) on pancreatic carcinogenesis in hamsters initiated with N-nitrosobis (2-oxopropyl) amine. *Pancreas*. 1994;9(1):78-82. [PubMed](#) | [CrossRef](#)
34. Sharma T, Baig MH, Khan MI, Alotaibi SS, Alorabi M, Dong JJ. Computational screening of camostate and related compounds against human TMPRSS2: A Potential Treatment of COVID-19. *Saudi Pharm J*. 2022. [PubMed](#) | [CrossRef](#)
35. Sun W, Zhang X, Cummings MD, Albarazanji K, Wu J, Wang M, et al. Targeting enteropeptidase with reversible covalent inhibitors to achieve metabolic benefits. *J Pharmacol Exp Ther*. 2020;375(3):510-21. [PubMed](#) | [CrossRef](#)
36. Ramsey ML, Nuttall J, Hart PA, Tactic Investigative Team. A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostate treatment in chronic pancreatitis (TACTIC). *Trials*. 2019;20(1):501. [PubMed](#) | [CrossRef](#)